Logan Collins, DO | |
2300 S 16th St, Lincoln, NE 68502-3704 | |
(402) 481-8566 | |
(402) 481-8805 |
Full Name | Logan Collins |
---|---|
Gender | Male |
Speciality | Hospitalist |
Experience | 7 Years |
Location | 2300 S 16th St, Lincoln, Nebraska |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1609300037 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208M00000X | Hospitalist | 2189 (Nebraska) | Secondary |
207R00000X | Internal Medicine | 2189 (Nebraska) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Bryan Medical Center | Lincoln, NE | Hospital |
Columbus Community Hospital | Columbus, NE | Hospital |
Beatrice Community Hospital & Health Center, Inc | Beatrice, NE | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Inpatient Physician Associates Grand Island Llc | 1254700495 | 20 |
Inpatient Physician Associates, Llc | 2365334364 | 76 |
News Archive
Nuvilex, Inc., announces today that Legacy Biotechnologies, Inc., its joint venture partner in Reme-Flu™, has commenced production of Reme-Flu™ and expects it to be ready for consumer purchase within the next 30 days. Reme-Flu™ is Legacy Biotechnologies' unique 2-part homeopathic flu remedy designed to help treat symptoms of the flu. Initially, Reme-Flu™ will be offered on the top-rated website, www.nutralegacy.com.
A 200-patient Phase 2 clinical pilot study will be initiated this month to test the efficacy and safety of a new use, and method of administering, an enzyme inhibitor for critically ill patients developed by University of California, San Diego Bioengineering Professor Geert Schmid-Sch-nbein. Conditions expected to qualify for the study include new-onset sepsis and septic shock, post-operative complications, and new-onset gastrointestinal bleeding.
A meeting with the US regulatory agency FDA held on July 17 has confirmed that the Swedish pharmaceutical company Orexo is on track with its preparation for a regulatory submission of a new drug approval (NDA) for its medicine for treatment of opioid dependency, OX219.
Columbia University Medical Center researchers have captured the first three-dimensional snapshots of the AMPA-subtype glutamate receptor in action. The receptor, which regulates most electrical signaling in the brain, is involved in several important brain activities, including memory and learning.
The next battle in the war on asthma symptom control could be a psychological one, a new study finds.
› Verified 2 days ago
Entity Name | Inpatient Physician Associates, Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1699725358 PECOS PAC ID: 2365334364 Enrollment ID: O20040325001149 |
News Archive
Nuvilex, Inc., announces today that Legacy Biotechnologies, Inc., its joint venture partner in Reme-Flu™, has commenced production of Reme-Flu™ and expects it to be ready for consumer purchase within the next 30 days. Reme-Flu™ is Legacy Biotechnologies' unique 2-part homeopathic flu remedy designed to help treat symptoms of the flu. Initially, Reme-Flu™ will be offered on the top-rated website, www.nutralegacy.com.
A 200-patient Phase 2 clinical pilot study will be initiated this month to test the efficacy and safety of a new use, and method of administering, an enzyme inhibitor for critically ill patients developed by University of California, San Diego Bioengineering Professor Geert Schmid-Sch-nbein. Conditions expected to qualify for the study include new-onset sepsis and septic shock, post-operative complications, and new-onset gastrointestinal bleeding.
A meeting with the US regulatory agency FDA held on July 17 has confirmed that the Swedish pharmaceutical company Orexo is on track with its preparation for a regulatory submission of a new drug approval (NDA) for its medicine for treatment of opioid dependency, OX219.
Columbia University Medical Center researchers have captured the first three-dimensional snapshots of the AMPA-subtype glutamate receptor in action. The receptor, which regulates most electrical signaling in the brain, is involved in several important brain activities, including memory and learning.
The next battle in the war on asthma symptom control could be a psychological one, a new study finds.
› Verified 2 days ago
Entity Name | Teledigm Physician Services Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1548667256 PECOS PAC ID: 6002130283 Enrollment ID: O20150116000478 |
News Archive
Nuvilex, Inc., announces today that Legacy Biotechnologies, Inc., its joint venture partner in Reme-Flu™, has commenced production of Reme-Flu™ and expects it to be ready for consumer purchase within the next 30 days. Reme-Flu™ is Legacy Biotechnologies' unique 2-part homeopathic flu remedy designed to help treat symptoms of the flu. Initially, Reme-Flu™ will be offered on the top-rated website, www.nutralegacy.com.
A 200-patient Phase 2 clinical pilot study will be initiated this month to test the efficacy and safety of a new use, and method of administering, an enzyme inhibitor for critically ill patients developed by University of California, San Diego Bioengineering Professor Geert Schmid-Sch-nbein. Conditions expected to qualify for the study include new-onset sepsis and septic shock, post-operative complications, and new-onset gastrointestinal bleeding.
A meeting with the US regulatory agency FDA held on July 17 has confirmed that the Swedish pharmaceutical company Orexo is on track with its preparation for a regulatory submission of a new drug approval (NDA) for its medicine for treatment of opioid dependency, OX219.
Columbia University Medical Center researchers have captured the first three-dimensional snapshots of the AMPA-subtype glutamate receptor in action. The receptor, which regulates most electrical signaling in the brain, is involved in several important brain activities, including memory and learning.
The next battle in the war on asthma symptom control could be a psychological one, a new study finds.
› Verified 2 days ago
Entity Name | Inpatient Physician Associates Grand Island Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1528796356 PECOS PAC ID: 1254700495 Enrollment ID: O20221212000509 |
News Archive
Nuvilex, Inc., announces today that Legacy Biotechnologies, Inc., its joint venture partner in Reme-Flu™, has commenced production of Reme-Flu™ and expects it to be ready for consumer purchase within the next 30 days. Reme-Flu™ is Legacy Biotechnologies' unique 2-part homeopathic flu remedy designed to help treat symptoms of the flu. Initially, Reme-Flu™ will be offered on the top-rated website, www.nutralegacy.com.
A 200-patient Phase 2 clinical pilot study will be initiated this month to test the efficacy and safety of a new use, and method of administering, an enzyme inhibitor for critically ill patients developed by University of California, San Diego Bioengineering Professor Geert Schmid-Sch-nbein. Conditions expected to qualify for the study include new-onset sepsis and septic shock, post-operative complications, and new-onset gastrointestinal bleeding.
A meeting with the US regulatory agency FDA held on July 17 has confirmed that the Swedish pharmaceutical company Orexo is on track with its preparation for a regulatory submission of a new drug approval (NDA) for its medicine for treatment of opioid dependency, OX219.
Columbia University Medical Center researchers have captured the first three-dimensional snapshots of the AMPA-subtype glutamate receptor in action. The receptor, which regulates most electrical signaling in the brain, is involved in several important brain activities, including memory and learning.
The next battle in the war on asthma symptom control could be a psychological one, a new study finds.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Logan Collins, DO 6101 Princess Margaret Dr, Lincoln, NE 68516-3127 Ph: (531) 207-8558 | Logan Collins, DO 2300 S 16th St, Lincoln, NE 68502-3704 Ph: (402) 481-8566 |
News Archive
Nuvilex, Inc., announces today that Legacy Biotechnologies, Inc., its joint venture partner in Reme-Flu™, has commenced production of Reme-Flu™ and expects it to be ready for consumer purchase within the next 30 days. Reme-Flu™ is Legacy Biotechnologies' unique 2-part homeopathic flu remedy designed to help treat symptoms of the flu. Initially, Reme-Flu™ will be offered on the top-rated website, www.nutralegacy.com.
A 200-patient Phase 2 clinical pilot study will be initiated this month to test the efficacy and safety of a new use, and method of administering, an enzyme inhibitor for critically ill patients developed by University of California, San Diego Bioengineering Professor Geert Schmid-Sch-nbein. Conditions expected to qualify for the study include new-onset sepsis and septic shock, post-operative complications, and new-onset gastrointestinal bleeding.
A meeting with the US regulatory agency FDA held on July 17 has confirmed that the Swedish pharmaceutical company Orexo is on track with its preparation for a regulatory submission of a new drug approval (NDA) for its medicine for treatment of opioid dependency, OX219.
Columbia University Medical Center researchers have captured the first three-dimensional snapshots of the AMPA-subtype glutamate receptor in action. The receptor, which regulates most electrical signaling in the brain, is involved in several important brain activities, including memory and learning.
The next battle in the war on asthma symptom control could be a psychological one, a new study finds.
› Verified 2 days ago
Ted M Triggs, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 555 S 70th St, Lincoln, NE 68510 Phone: 402-219-8747 Fax: 402-219-8748 | |
Joseph L Kummer, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1600 S 48th St, Suite 600, Lincoln, NE 68506 Phone: 402-483-3333 Fax: 402-483-3297 | |
Brenda Kay Bell, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1919 S 40th, Ste 207, Lincoln, NE 68506 Phone: 402-489-3383 Fax: 402-489-3789 | |
Scott Allen Heasty, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2300 S 16th St, Lincoln, NE 68502 Phone: 402-481-4780 Fax: 402-481-5377 | |
Scott Charles Rasmussen, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 3901 Pine Lake Rd, Suite 220, Lincoln, NE 68516 Phone: 402-421-3240 Fax: 402-423-0739 | |
Jeffrey E Jarrett, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 S 48th St, Suite 800, Lincoln, NE 68506 Phone: 402-483-8600 Fax: 402-483-8689 | |
Tracy L Slocum Farritor, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 555 S 70th St, Lincoln, NE 68510 Phone: 402-219-8747 Fax: 402-219-8748 |